BENEFITS OF
NINLARO® (IXAZOMIB)
Overview of the NINLARO study*
The treatment combination of NINLARO + lenalidomide + dexamethasone was tested in a clinical study compared to placebo + lenalidomide + dexamethasone in people whose multiple myeloma had returned. This study evaluated the efficacy and safety profile of NINLARO in combination with lenalidomide + dexamethasone.
The study compared a three medication vs a two medication combination†
*The US Food and Drug Administration (FDA) approved NINLARO based on the results of this clinical study. This study tested the NINLARO treatment combination (NINLARO + lenalidomide + dexamethasone) compared with placebo + lenalidomide + dexamethasone in 722 people whose multiple myeloma had come back or stopped responding to prior therapy. It measured the length of time a patient lived without their disease getting worse.
†Placebo pills are not active.
When multiple myeloma returns, taking the NINLARO treatment combination may help you live longer without your multiple myeloma getting worse
The NINLARO treatment combination (NINLARO + lenalidomide + dexamethasone) was proven to be an effective treatment for people whose multiple myeloma had come back or stopped responding to prior therapy.
Progression-free survival (PFS)
In the clinical study, people taking the NINLARO treatment combination went more than a year and a half (20.6 months) without their multiple myeloma getting worse compared to 14.7 months for people who took the lenalidomide + dexamethasone combination alone.
The NINLARO treatment combination improved the
time people lived without their disease getting worse
‡NINLARO combination=NINLARO + lenalidomide + dexamethasone; lenalidomide + dexamethasone combination=placebo + lenalidomide + dexamethasone.
Overall survival
In this study, people taking the NINLARO treatment combination lived a similar overall length of time after diagnosis as people who received the lenalidomide+dexamethasone combination alone.
The NINLARO treatment combination was proven to work quickly and effectively
§A 90% or greater decrease in M protein (an abnormal myeloma protein produced by myeloma cells). Also called very good partial remission.
‖‖Complete response is when there are less than 5% plasma cells in the bone marrow and blood and urine lab tests show no M protein.